Metamizole Abz

Metamizole, the active ingredient in Metamizole Abz, is a pyrazolone presented as an oral formulation for oral use. It is employed to relieve pain, reduce fever, and provide postoperative analgesia in adult patients. GNH USA supplies Metamizole Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole belongs to the pyrazolone class and is used for conditions that require analgesic or antipyretic therapy.

Pain: provides effective relief of moderate to severe acute pain. Fever: reduces elevated body temperature in febrile states. Postoperative analgesia: helps control pain after surgical procedures.

Metamizole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Dizziness or light‑headedness. - Mild skin rash or itching. - Transient low blood pressure. - Temporary reduction in white blood cell count.

Serious or Rare Side Effects: - Agranulocytosis, a potentially life‑threatening drop in neutrophils. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Anaphylactic shock or severe allergic response. - Significant liver enzyme elevation. - Hematologic disorders including thrombocytopenia.

Before prescribing Metamizole, clinicians should consider several safety measures.

Assess renal function: adjust use in patients with impaired kidney function. Monitor blood counts: regular hematologic testing is advised due to risk of agranulocytosis. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Use caution in hepatic impairment: liver disease may increase toxicity. Avoid concomitant use with other myelotoxic agents: combined risk of blood dyscrasias. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metamizole can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other myelotoxic drugs (e.g., chemotherapy) – heightened risk of severe neutropenia. - Combination with sulfonamide antibiotics – increased incidence of blood dyscrasias.

Moderate Interactions (Monitor Closely): - Concurrent NSAIDs – additive gastrointestinal irritation. - Anticoagulants – potential for enhanced bleeding tendency. - ACE inhibitors – may exacerbate hypotensive effects. - Diuretics – possible reduction in renal clearance of Metamizole.